Basaglar (Insulin Glargine) Injection shortage
Not a nationwide shortage — Eli Lilly and has told the FDA it is discontinuing its insulin glargine injections. The FDA lists this under “To be discontinued” as of Oct 5, 2026: a company stopping its own product. 2 other companies sell the same medicine and have not reported a problem, so your pharmacy may be able to order another company’s version.
Eli Lilly is permanently stopping the Insulin Glargine U-100 Tempo Pen. Other insulin glargine products — including Basaglar KwikPen, Lantus SoloStar, and Toujeo — are still listed as available from other manufacturers.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this medicine? See the ‘What to do’ note from Dr. Brian Staiger, PharmD →Is Basaglar still in shortage? — status as of Oct 5, 2026
Still listed as “To be discontinued” as of Oct 5, 2026. Eli Lilly and is stopping its own version only; 2 other companies still sell the same medicine and have not reported a problem. Your pharmacy may need to order another company’s version.
The charts count only the companies that reported this shortage to the FDA; companies that haven’t reported a problem are in the green card, and the Supply-Risk rating counts them too.
Shortage timeline
-
Oct 24, 2025Currently in shortage1 of 1 product affected.
-
Oct 24, 2025First reported to the FDA1 product first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
Which Basaglar products are affected — by company
Company: Eli Lilly and Co. 📞 800-545-5979 1 NDC click to expand
| Status | NDC / product | Strength / size | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Basaglar Injection | U-100 Tempo Pen | — | A business decision was made to discontinue manufacture of the drug. | — |
These rows are company reports to the FDA for Insulin Glargine Injection — they do not cover every company that lists this medicine. A company appears here only if it told the FDA it has a supply problem, so other companies may still have stock. That’s the basis for the Where else can I get Basaglar or its generic? options further down this page.
Why is Eli Lilly and discontinuing Basaglar?
Eli Lilly has made a business decision to permanently stop making Basaglar U-100 insulin glargine in the Tempo Pen format (the specific product with NDC 0002-8214-05). No specific public reason beyond it being a business decision was shared with the FDA — so unfortunately, there's no deeper explanation available here.
It's worth knowing that this report covers only this particular Lilly product and package. It does not mean that all forms of Basaglar or all insulin glargine products from every manufacturer are going away — only this specific Tempo Pen version from Lilly is being discontinued.
Based on the company-reported reason(s) and notes on file with the FDA for Insulin Glargine Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as companies report changes.
What should I do if I take Basaglar?
Insulin glargine (the Basaglar U-100 Tempo Pen) is currently on the FDA shortage list. I want to walk you through what this means so you can plan your next steps calmly.
The affected product is the Basaglar U-100 Tempo Pen, and right now there is no available source reported for it. The reason listed is a business decision by Eli Lilly to discontinue making this particular pen. Because it is being discontinued, this supply problem may be permanent, so a conversation with your prescriber is the right next step to plan ahead.
Please keep in mind that this record reflects only the manufacturer that filed it. Insulin glargine — the same active medicine — is still made in other forms and by other makers, including Basaglar Kwikpen, Lantus, Lantus Solostar, and Toujeo.
Here is what I suggest, in order:
- Do not stop, skip, or change your insulin on your own — steady dosing matters.
- Ask your prescriber or pharmacist about another insulin glargine product from the list above; your pharmacy may be able to source one, though it may not be in local stock.
- Because this pen is being discontinued, plan a prescriber visit to choose your next option.
The manufacturer's contact number is listed on this page for reference; pharmacies usually handle these calls. This is general national information and may not match your local pharmacy's actual stock.
- Ask your pharmacy to check other companies’ versions, other strengths / sizes, package sizes, and nearby stores — the options below are a starting point.
- If this is part of an ongoing or essential regimen (for example HIV, seizure, heart, transplant, diabetes or mental-health medicines), arrange continued supply before you run out rather than rationing doses.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Basaglar or its generic?
FDA shortages are company-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every company that lists insulin glargine injections is necessarily short. Below are the other listings in the current FDA NDC Directory that are not reported in shortage: the same medicine from companies that haven’t reported a problem (the reporting company is excluded), and other dosage forms. These are generic versions of Basaglar — a switch from the brand goes through your pharmacist or prescriber. Some listings are repackagers, which relabel another company’s product. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine from other companies (not reporting a shortage)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from companies that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Company | NDC |
|---|---|---|---|---|
| Toujeo | INSULIN GLARGINE 300 U/mL | Injection, Solution · Subcutaneous | Sanofi-Aventis U.S. LLC | 00024-5869-00 |
| Lantus Solostar | INSULIN GLARGINE 100 [iU]/mL | Injection, Solution · Subcutaneous | sanofi-aventis U.S. LLC | 00088-2219-00 |
| Insulin Glargine U-300 Max | INSULIN GLARGINE 300 [iU]/mL | Injection, Solution · Subcutaneous | Sanofi-Aventis U.S. LLC | 00955-2900-02 |
| Lantus | INSULIN GLARGINE 100 [iU]/mL | Injection, Solution · Subcutaneous | A-S Medication Solutions | 50090-0876-00 |
| Toujeo | INSULIN GLARGINE 300 U/mL | Injection, Solution · Subcutaneous | A-S Medication Solutions | 50090-2193-00 |
Therapeutic equivalents & pricing 8 productsclick to expand
Orange Book–rated equivalents of the affected strengths / sizes, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Lantus 100 [iU]/mL | sanofi-aventis | 1 vial | $6.152 | — | Availability likely |
| BASAGLAR KwikPen 100 [iU]/mL | Eli | 5 syringes | $20.935 | — | Availability likely |
| BASAGLAR Tempo Pen 100 [iU]/mL | Eli | 5 syringes | $20.955 | — | Discontinued |
| Lantus 100 [iU]/mL | A-S | 10 ml | — | — | FDA listed |
| Lantus Solostar 100 [iU]/mL | A-S | 5 syringes | — | — | FDA listed |
| Lantus Solostar 100 [iU]/mL | A-S | 5 syringes | — | — | FDA listed |
| Insulin Glargine Solostar 100 [iU]/mL | A-S | 5 syringes | — | — | Discontinued |
| Lantus Solostar 100 [iU]/mL | sanofi-aventis | 1 syringe | — | — | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Basaglar — that fall in the same broad treatment class (insulins) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Codes & classification for pharmacists and billers
Where does this data come from?
Other endocrinology/metabolism shortages
Basaglar shortage FAQs
Is Basaglar still in shortage?
Which Basaglar products are affected?
When will Basaglar be available again?
Can I still get Basaglar or its generic somewhere?
Is the brand or the generic affected?
What should I do if I take Basaglar?
Still have a question about the Basaglar shortage?
Ask a pharmacist about this shortage →View Insulin Glargine Injection on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (companies listing the same ingredient & form — the "other companies" the rating counts); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.